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 Implication for health policy/practice/research/medical education:
The significant relations between the increased HO-1 expression and oxidative stress biomarkers in patients with CLD suggest that 
HO-1 may play an important role to protect the liver from oxidative stress-dependent damage. Reading this article is recommended 
to all internists and hepatologists.
Background: Chronic liver disease (CLD) is a global medical problem. This disease is as-
sociated with increased hepatic oxidative stress. One of the antioxidant enzymes that 
protect cells against this stress is heme oxygenase-1 (HO-1). 
Objectives: This study aimed to investigate the mRNA expression of HO-1 in Egyptian pa-
tients with CLD and its relation to oxidative stress biomarkers.
Patients and Methods: Levels of serum ferritin, carboxyhemoglobin, malondialdehyde 
(MDA), and erythrocyte-reduced glutathione (GSH) were measured, and HO-1 mRNA ex-
pression was detected in 45 CLD patients (15 with nonalcoholic steatohepatitis [NASH], 15 
with chronic hepatitis C, and 15 with liver cirrhosis) and 15 healthy controls.
Results: HO-1 mRNA expression was increased in patients with NASH, chronic hepatitis 
C, and liver cirrhosis compared to controls. The expression in cirrhotic patients was sig-
nificantly higher than that in patients with NASH and chronic hepatitis C. Compared to 
controls, patients with NASH, chronic hepatitis C, and liver cirrhosis had higher levels of 
ferritin, carboxyhemoglobin, and MDA and lower levels of GSH. HO-1 mRNA expression 
was positively correlated with levels of carboxyhemoglobin, serum ferritin, and serum 
MDA and negatively correlated with levels of erythrocyte GSH in CLD patients. 
Conclusions: HO-1 mRNA expression was significantly increased in CLD patients, and 
the increase reflected the severity of the disease. The significant relationship between 
the increased HO-1 expression and oxidative stress biomarkers in patients with CLD sug-
gests that HO-1 may play an important role in protecting the liver from oxidative stress-
dependent damage. Therefore, induction of HO-1 could be a novel therapeutic option for 
CLD. Copyright  c 2012 Kowsar Corp. All rights reserved.
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1. Background
Chronic liver disease (CLD) is an important cause of 
morbidity and mortality and represents a major health 
problem worldwide. Liver cirrhosis is the final common 
pathway of many cases of CLD; however, the exact point 
at which a disease process produces cirrhosis is difficult 
to define (1). Hepatitis C virus (HCV) infection causes 
liver disease characterized by inflammation, cell dam-
age, and progressive liver fibrosis leading to cirrhosis (2). 
Non-alcoholic steatohepatitis (NASH) is a clinical-patho-
logical condition characterized by a necroinflammatory 
disorder with fatty infiltration of hepatocytes and may 
progress to fibrosis or cirrhosis, with a fatal outcome (3). 
Although the precise molecular mechanisms by which 
HCV causes liver injury are not fully understood, recent 
evidence demonstrates that HCV causes oxidative stress 
in human liver cells, due to the generation of reactive 
oxygen species (ROS) (4-6). Moreover, oxidative stress 
and lipid peroxidation play an important role in the 
pathogenesis of NASH, as their end products can induce 
hepatocellular injury and fibrogenesis (7-9). The liver is 
the major organ that detoxifies excess heme molecules 
by the action of the heme oxygenase (HO) enzyme that 
catalyzes the initial and rate-limiting reaction in heme 
catabolism and cleaves pro-oxidant heme to form iron, 
carbon monoxide (CO), and biliverdin, which is subse-
quently converted to bilirubin by biliverdin reductase 
(10). The liver contains 2 HO isozymes for physiologic deg-
radation of the heme; HO-1 is inducible various stimuli, 
including cytokines, heavy metals, and reactive oxygen 
species, while HO-2 is constitutively produced. The anti-
oxidant property of HO is derived from the elimination 
of pro-oxidant heme and from the biological activities of 
its reaction products: biliverdin, bilirubin, and iron (11). 
Overproduction of biliverdin and bilirubin serves as an 
antioxidative defense mechanism (12). Free iron inhib-
its the de novo synthesis of heme, binds to iron regula-
tory protein, and stimulates the biosynthesis of ferritin, 
which exerts an additional antioxidant effect. Another 
important role of the HO reaction in regulating liver 
function is to generate CO, which has anti-inflammatory 
effects and acts as an endogenous regulator to maintain 
microvascular blood flow (13). CO regulates the hepatic 
vascular tone in a variety of experimental models of con-
ditions such as ischemia-reperfusion, endotoxemia, and 
heme overloading (14, 15). Recently, much attention has 
been paid to physiologic and pathophysiologic roles of 
the HO enzyme in organ homeostasis (16). HO-1 has po-
tent cytoprotective effects; it is an anti-oxidant defense 
enzyme that converts potentially toxic heme into anti-ox-
idants (17) and is a stress-responsive protein that is essen-
tial for higher eukaryotes to cope with cellular stress and 
to regulate cellular iron metabolism (18, 19). Considering 
these findings, we investigated the relation between HO-1 
mRNA expression in Egyptian patients with CLD and oxi-
dative stress biomarkers.
2. Objectives
This study investigated the mRNA expression of HO-1 in 
Egyptian patients with CLD and the relation of HO-1 ex-
pression with oxidative stress biomarkers.
3. Patients and Methods
3.1. Patients
We randomly selected 45 Egyptian patients with CLD 
from those admitted to the Internal Medicine Depart-
ment in the Tanta University Hospital between April 
2010 and March 2011. The cohort consisted of 15 patients 
with NASH (6 men and 9 women) with a mean age of 53 
± 8.9 years, 15 patients with chronic hepatitis C (6 men 
and 9 women) with a mean age of 52 ± 8.2 years, and 15 
patients with liver cirrhosis (8 men and 7 women) with 
a mean age of 54.5 ± 7.6 years. The study protocol was 
approved by the General Ethics Council of the Tanta 
University Hospital, Tanta University, Tanta, Egypt, and 
all patients gave their informed consent to participate 
in the study. The diagnosis of NASH was established on 
the basis of the following clinical and histopathological 
features: (i) abnormal liver biochemistry for more than 
3 months; (ii) liver biopsy showing steatosis (10%) in the 
presence of lobular and/or portal inflammation, with or 
without Mallory bodies or fibrosis; and (iii) the exclusion 
of other liver diseases. Diagnosis of chronic hepatitis C 
was established by serological detection of anti-HCV an-
tibodies and HCV-RNA, and serum transaminase levels 
greater than 3 times the upper limit of normal for at least 
6 months, and confirmed by liver biopsy. The diagnosis 
of liver cirrhosis was established on the basis of clini-
cal, biochemical, histological, and ultrasound findings. 
The etiology of cirrhosis was HCV-related in 8 patients, 
NASH in 4, and cryptogenic in 3 patients. In addition, all 
cirrhotic patients had schistosomal periportal hepatic fi-
brosis. Severity of the liver disease was scored according 
to Child-Pugh classification (20). Other causes of chronic 
liver disease, including drugs, alcohol, chronic hepatitis 
B virus (HBV) infection, autoimmune liver disease, hered-
itary hemochromatosis, Wilson disease, and α-1 antitryp-
sin deficiency, were excluded by appropriate serological 
studies and findings for liver biopsy samples. Hepatocel-
lular carcinoma was ruled out by abdominal ultrasound, 
spiral abdominal computed tomography, and alpha feto-
protein determination. Patients did not receive antioxi-
dant vitamin or selenium supplementation within the 2 
months preceding their inclusion in the study.
3.2. Controls
Fifteen healthy age- and sex-matched volunteers (9 men 
and 6 women) with a mean age of 50 ± 3.9 years were re-
cruited for participation as controls. They were selected 
from medical and paramedical staff and from blood do-
nors in the Tanta University Hospital. They gave informed 
consent to participate in the study. They were seronega-280 Hepat Mon. 2012;12(4)
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tive for viral hepatitis markers, and for none of them, 
liver function tests yielded abnormal results.
3.3 Blood Collection and Biochemical Analysis
Fasting blood samples were obtained aseptically from 
patients and controls and divided into 3 parts; one part 
was collected in a vacutainer plain tube without antico-
agulant, incubated at 37 ºC for half an hour, and centri-
fuged at 3,000 ×g for 10 min. This serum sample was used 
for determination of liver function tests, using conven-
tional methods of clinical chemistry, alpha fetoprotein 
estimation by radioimmunoassay, anti-HCV antibodies 
detection using commercially available enzyme-linked 
immunoassay along with serum HCV RNA determina-
tion by reverse transcription-polymerase chain reaction 
(RT-PCR), HBV surface antigen and HBV core antibodies 
detection by commercial assays, determination of fer-
ritin levels using a kit supplied from Biosystems (21), 
determination of lipid peroxidation end-product and 
malondialdehyde (MDA) levels by the thiobarbituric 
acid method (22). The second fraction was drawn into 
ethylenediaminetetraacetic acid (EDTA) tubes for estima-
tion of the percent saturation of hemoglobin by carbon 
monoxide, i.e., carboxyhemoglobin (COHb) concentra-
tion, as an indicator of HO-1 activity, using spectropho-
tometry as previously described (23). The erythrocyte 
pellet was washed 3 times with cold isotonic saline and 
then diluted with saline to the original blood volume. 
Hemoglobin concentration was determined using a kit 
supplied by BioMeriux, France. The erythrocyte-reduced 
GSH level was measured as previously described (24) and 
expressed as mmol/g Hb. The third part was collected in 
a heparin sterile vacutainer for determination of HO-1 
mRNA expression by RT-PCR. Total RNA was extracted 
from peripheral blood mononuclear cells (PBMCs) us-
ing a total RNA isolation system from Promega Corpora-
tion, Madison, USA (25). RT-PCR reaction for HO mRNA 
was performed using QIAGEN’s 1-step RT-PCR kit (Hilden, 
Germany), according to the manufacturer’s instructions. 
The final concentrations of the reaction components (50 
µL) were 1× QIAGEN buffer, 400 µM of each dNTP, 0.6 µM 
of both sense and antisense HO primers, 2 µL of RT-PCR 
enzyme mix, 5 units of RNase inhibitor, and 2 µg of total 
RNA. Reverse transcription was achieved by heating the 
reaction components at 50 ºC for 30 min. The initial PCR 
activation step was performed by heating at 95 ºC for 15 
min. The amplification reaction was carried out by ther-
mal cycler (model 9600, Perkin-Elmer) for 35 cycles of de-
naturation at 94 ºC for 1 min, annealing at 55 ºC for 1 min, 
and extension at 72 ºC for 1 min, followed by a final exten-
sion step of 72 ºC for 10 min. The HO complementary DNA 
(cDNA) was amplified using the following primers: sense, 
5′-CAGGCAGAGAATGCTGAGTTC-3′ and antisense, 5′-GAT-
GTTGAGCAGGAACGCAGT-3′ (26). ß-actin was used as a 
housekeeping gene with the following primers: sense, 
5›-TTCTTTGCAGCTCCTTCGTTGCCG-3› and antisense, 5›-TG-
GATGGCTACGTACATGGCTGGG-3›. The amplified product 
for HO was separated on 2% agarose gel and visualized 
by ethidium bromide staining under ultraviolet light. 
Primers for HO were synthesized by Metabion Interna-
tional AG (Martinsried, Germany). The RT-PCR reactions 
were performed with a Hybaid thermal cycler (Thermo 
Electron corporation [formerly Hybaid], Waltham, MA, 
USA). The molecular weight was determined using a DNA 
ladder purchased from Promega (Madison, WI, USA). The 
computer program “Quantity one” (version 4.6.3, Bio-
Rad, USA) was used to analyze the intensities of the PCR 
bands. 
3.4. Statistical Analysis
Results were expressed as mean ± standard deviation 
(SD). Comparisons between groups were made using 
Student´s t-test for continuous variables. The correlation 
between 2 parameters was determined by Pearson’s cor-
relation coefficient (r). A P value of less than 0.05 was con-
sidered statistically significant.
4. Results
The main clinical and biochemical characteristics of 
patients with CLD are presented in Table 1. HO-1 mRNA 
expression was determined by RT-PCR, as shown in 
Figure 1. The densities of the bands are expressed in ar-
bitrary units. HO-1 mRNA expression in patients with 
NASH, chronic hepatitis C, and liver cirrhosis was more 
than that in controls (P < 0.05, P < 0.001, and P < 0.001, 
Lane M, DNA molecular marker; Lane 1, blank; Lane 2, Control; Lane 3, non-
alcoholic steatohepatitis; Lane 4, chronic hepatitis C; Lane 5, liver cirrhosis 
(bp = base pair)
Figure 1. Representative Agarose Gel Electrophoresis for Amplified PCR 
Product of Heme Oxygenase-1 Gene at 550 bp and ß-actin at 457 bp as a 
Housekeeping Gene. 281 Hepat Mon. 2012;12(4)
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respectively). Further, compared to patients with NASH 
and chronic hepatitis C, patients with cirrhosis had sig-
nificantly higher HO expression (P  < 0.001, for both). 
HO-1 mRNA expression in chronic hepatitis C patients 
was significantly more than that in patients with NASH (P 
< 0.001), as shown in Table 1 and Figure 2. Serum ferritin, 
carboxyhemoglobin, and serum MDA levels in patients 
with NASH, chronic hepatitis C, and liver cirrhosis were 
significantly higher than the levels in healthy controls. 
These levels were elevated in cirrhotic patients compared 
to NASH and chronic hepatitis C patients. Moreover, the 
levels in patients with chronic hepatitis C were higher 
than those in patients with NASH (P < 0.01, P < 0.001, and 
P < 0.001, respectively). On the other hand, erythrocyte 
GSH levels were decreased in patients with NASH, chronic 
hepatitis C, and liver cirrhosis compared to controls (P < 
0.001, for all) and were significantly lower in cirrhotic pa-
tients than in NASH and chronic hepatitis C patients (P 
< 0.001, for both). Moreover, the erythrocyte GSH level in 
patients with chronic hepatitis C was significantly lower 
than those in patients with NASH (P < 0.001) as shown in 
Table 1. Table 2 shows that the HO-1 mRNA expression in 
Child-Pugh class C was more than that in Child-Pugh class 
A and B (P < 0.001 and P < 0.05, respectively). Moreover, 
serum ferritin, carboxyhemoglobin, and serum MDA lev-
els in Child-Pugh class C were significantly higher than 
those in class A and B. In contrast, erythrocyte GSH level 
in Child-Pugh class C was lesser than that in class A and 
B (P < 0.001, for both). In the present study, HO-1 mRNA 
expression was positively correlated with levels of car-
boxyhemoglobin (r = 0.963, P < 0.001), serum ferritin (r 
= 0.868, P < 0.001), and serum MDA (r = 0.978, P < 0.001) 
and negatively correlated with erythrocyte GSH level (r = 
-0.937, P < 0.001) in CLD patients, as shown in Figure 3.
5. Discussion 
HO-1 is an enzyme that catalyzes the rate-limiting step 
in heme degradation to result in the formation of iron, 
carbon monoxide, and biliverdin, which is subsequently 
converted to bilirubin by biliverdin reductase. The bio-
logical effects exerted by the products of this enzymatic 
Figure 2.  Mean + S. D. of Heme Oxygenase-1 mRNA Expression in Patients 
With  Chronic Liver Disease and Controls
Figure 3. Correlation Between Heme Oxygenase-1 mRNA Expression and Carboxyhemoglobin Concentration (A), Serum Ferritin Level (B), 
Serum Malondialdehyde Level (C) and Reduced Glutathione Level (D) in Patients With Chronic Liver Disease282 Hepat Mon. 2012;12(4)
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reaction have gained much attention. The anti-oxidant, 
anti-inflammatory, and cytoprotective functions associ-
ated with HO-1 are attributable to 1 or more of its degrada-
tion products. Induction of HO-1 occurs as an adaptive 
and beneficial response to various injurious stimuli such 
as oxidative stress, and this inducible nature of HO-1 sig-
nifies its importance in several pathophysiological states 
such as liver diseases. Thus, HO-1 has emerged as a key tar-
get molecule with therapeutic implications (27). This 
study investigated the mRNA expression of HO-1 in Egyp-
tian patients with CLD and its relation to oxidative stress 
biomarkers, and we showed that HO-1 mRNA expression 
was increased in patients with NASH, chronic hepatitis C, 
and liver cirrhosis compared to controls. HO-1 expression 
in cirrhotic patients was significantly higher than that in 
patients with NASH and chronic hepatitis C. The HO-1 
mRNA expression was increased in Child-Pugh class C 
compared to Child-Pugh class A and B. Furthermore, HO-1 
mRNA expression in CLD patients was positively corre-
lated with levels of carboxyhemoglobin, serum ferritin, 
and serum MDA and negatively correlated with level of 
erythrocyte GSH. These results are in agreement with the 
findings of Malaguarnera et al. (28), who showed that 
HO-1 expression was significantly increased in NASH pa-
tients, and the increase reflected the severity of the dis-
ease. They observed a significant correlation between the 
increased levels of HO-1 and ferritin and between the in-
creased levels of HO-1 and lipid peroxidation. Moreover, 
NASH patients with lower levels of GSH exhibited higher 
expression of HO-1. Thus, the induction of HO-1 is an adap-
Characteristic Controls (n = 15) NASH n (n = 15) HCV n (n = 15) Liver Cirrhosis (n = 15)




























ALT n, U/L, mean ± SD 23.87 ± 5.05 50.6 ± 20.3 a 60.4 ± 23.53 d 62.4 ± 25.6 i
AST n, U/L, mean ± SD 22.77 ± 4.06 48.53 ± 20.34 a 55 ± 21 d 80.67 ± 30.72 i,k,m
Serum bilirubin, mg/dL, mean ± SD 0.58 ± 0.22 0.8 ± 0.21c 1.12 ± 0.52 e,h 1.78 ± 1.07i,k,m
Serum albumin, g/L, mean ± SD 43.5 ± 2.2 42.2 ± 2.8 41.7 ± 3.5 29.3 ± 3.4 i,j,l
Prothrombin activity, %, mean ± SD 95 ± 3.31 93 ± 3.9 92 ± 4.8 72.2 ± 6.5 i,j
Serum ferritin , ng/mL, mean ± SD 92.13 ± 59.46 1.25 ± 0.3 b 309.8 ± 92.19 d,g 845.27 ± 129.97 i,j,l
Carboxyhemoglobin , %, mean ± SD 0.96 ± 0.13 1.25 ± 0.3 b 1.84 ± 0.43 d 2.33 ± 0.53 i,j,m
MDA n, µmol/L, mean ± SD 1.12 ± 0.19 1.51 ± 0.24a 2.09 ± 0.4 d,f 2.49 ± 0.6 i,j,m
GSH n, µmol/g Hb, mean ± SD 4.55 ± 0.24 4.06 ± 0.11a 3.79 ± 0.13 d,f 3.39 ± 0.21 i,j,l 
HO-1 n mRNA expression (arbitrary units), 
mean ± SD
110.4 ± 26.63 130 ± 24.06 c 168.47 ± 20.16 d 207.73 ± 25.54 i,j,l
Table 1. Clinical and Biochemical Characteristics of Patients With Chronic Liver Disease and Controls
a P < 0.001, b P < 0.01, c P < 0.05 NASH vs. controls; d P < 0.001, e P < 0.01 HCV vs. controls; f P < 0.001, g P < 0.01, h P < 0.05 HCV vs. NASH; i P < 0.001 liver cir-
rhosis vs. controls; j P < 0.001, k P < 0.01 liver cirrhosis vs. NASH; l P < 0.001, m P < 0.05 liver cirrhosis vs. HCV  
n Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; GSH, reduced glutathione; HCV, hepatitis c virus; HO-1, heme oxygenase-1; MDA, 
malondialdehyde; NASH, non-alcoholic steatohepatitis 
Class A (n=45) Class B (n=45) Class C (n=45)
Patients, No. (%) 18 (40) 16 (35.6) 11 (24.4)
Serum ferritin, ng/mL, mean ± SD 280.83 ± 134.44 736.56±162.96 a 928.33 ± 129.54 c,e
Carboxyhemoglobin, %, mean ± SD 1.54 ± 0.47 2.23 ± 0.52 a 2.63 ± 0.47 c,f
MDA, µmol/L, mean ± SD 1.79 ± 0.43 2.37 ± 0.5 b 2.85 ± 0.6 c,f
GSH, µmol/g Hb, mean ± SD 3.94 ± 0.13 3.47 ± 0.2 a 3.01 ± 0.21 c,d
HO-1 mRNA expression (arbitrary units), mean ± SD 149.87 ± 29.76 197.78 ± 27.77 a 219.5 ± 23.05 c,f
Table 2. Ferritin Level, Carboxyhemoglobin Concentration, Malondialdehyde (MDA) Level, Reduced Glutathione (GSH) Level and Heme Oxygenase-1 (HO-
1) mRNA Expression Among  Patients With Chronic Liver Disease According to Child-Pugh Classification
a P < 0.001, b P < 0.01 class B vs. class A; c P < 0.001 class C vs. Class A; d P < 0.001, e P < 0.01, f P < 0.05 class C vs. class B.283 Hepat Mon. 2012;12(4)
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tive response against oxidative damage elicited by lipid 
peroxidation, and this may be critical in the progression 
of the disease. This was supported by Nan et al. (29), who 
reported that HO-1 plays an important role in NASH. Re-
garding alcoholic steatohepatitis, Yao et al. (30) have 
shown that the induction of HO-1 by Ginkgo biloba is as-
sociated with a decrease in liver damage caused by etha-
nol feeding for 90 d in rats. This is probably due to the 
enhanced anti-oxidative capacity against ethanol-in-
duced oxidative stress and maintenance of cellular redox 
balance (31, 32). Conflicting data are available on HO-1 in 
hepatitis C. Ghaziani et al. (33) demonstrated that HCV-
expressing human hepatoma cells have increased levels 
of HO-1 and decreased Bach 1 expression. Abdalla et al. 
(34), on the contrary, observed a decrease in HO-1 and 
HO-1 mRNA in liver biopsies from HCV-infected patients. 
The expression of HO-1 was also reduced in cell lines that 
stably express the HCV core protein, which suggests that 
core gene products are capable of regulating HO-1 expres-
sion. Clearly, further studies are necessary to reconcile 
these conflicting results. Concerning the effects of HO-1 
induction on hepatitis C, Shan et al. (35) have shown a de-
crease in HCV replication, an effect similar to that de-
scribed by Protzer et al. (36), in HBV infection. Moreover, 
Zhu et al. (37) showed that targeted overexpression of 
HO-1 led to a significant inhibition of HCV replication 
without affecting other parameters of cell viability in hu-
man hepatoma cells. These studies have recently been 
extended by others, who have shown that the HO-1 prod-
uct biliverdin interfered with HCV replication via direct 
modulation of the antiviral interferon-α response in 2 hu-
man hepatoma replicon cell lines (38). Thus, HO-1 might 
serve as a specific therapeutic target for the treatment of 
chronic HCV infection, although the results are some-
what contradictory. With respect to liver cirrhosis, Wei et 
al. (39) have shown that HO-1 mRNA and protein expres-
sion is increased in hepatocytes and some Kupffer cells in 
the early phase of the disease, while HO-2 expression in 
these cells is unchanged. In cirrhotic livers, mainly those 
with biliary cirrhosis, both HO-1 and HO-2 are increased, 
as shown by Goh et al. (40). HO-1 was localized mainly in 
Kupffer cells, while HO-2 was localized in the cytoplasm 
of the hepatocytes. Similar results were obtained by 
Makino et al. (41) in patients with post-hepatic cirrhosis. 
They showed that HO-1 expression increased in the liver, 
being mainly distributed in Kupffer cells and hepato-
cytes. Moreover, a study on cirrhotic patients undergoing 
liver transplantation has shown that HO-1 is upregulated 
through heme-independent stimuli, according to the de-
velopment of portal hypertension, and that induced HO-1 
plays a pathophysiological role in portal hypertension 
through CO production (42). In the current study, car-
boxyhemoglobin concentration in patients with NASH, 
chronic hepatitis C, and liver cirrhosis was significantly 
higher than that in healthy controls. The concentration 
was elevated in cirrhotic patients compared to NASH and 
chronic hepatitis C patients. These results are consistent 
with the findings of previous studies (43, 44). In cirrhotic 
patients with spontaneous bacterial peritonitis, CO pro-
duction, evaluated as the CO concentration in the ex-
haled air and blood CO-Hb level, is further increased and 
may participate in circulatory alterations (23). In our 
study, levels of serum ferritin in patients with NASH, 
chronic hepatitis C, and liver cirrhosis were significantly 
higher than those in healthy controls. High ferritin levels 
have previously been reported in NASH (28) and chronic 
HCV-related hepatitis (45, 46), and our study clearly con-
firms this finding. An imbalance in the pro-oxidant/anti-
oxidant equilibrium in favor of pro-oxidants constitutes 
the oxidative stress phenomenon, a condition that may 
induce a number of pathophysiological events in the liv-
er (9). In this study, serum MDA level was significantly 
higher and erythrocyte GSH level was significantly lower 
in patients with NASH than in healthy controls. Similar 
findings were reported by previous studies (7, 28,47). 
Meanwhile, we also observed that compared to healthy 
controls, patients with chronic hepatitis C had higher se-
rum MDA and lower erythrocyte GSH levels. These results 
are in accordance with the findings of other studies (4, 
6,48). The present study provided evidence for the protec-
tive role of HO-1 in the body’s response to oxidative stress. 
Due to its beneficial effects, the targeted induction of 
HO-1 is considered to have major therapeutic potential 
for the treatment of inflammatory liver diseases to pre-
vent progression of early stages of liver injury (49). In 
this context, it is interesting to note that induction of 
HO-1 expression by natural compounds contributes to 
protection against liver damage in various experimental 
models (50). Current knowledge on the applications of 
HO-1 as a therapeutic target still seems precocious and 
critical questions remain to be answered before clinical 
interventions become available. Because induction of 
HO-1 expression may hold therapeutic promises, studies 
designed to identify clinically relevant methods of deliv-
ering such treatment, such as gene therapy to increase 
the induction of HO-1 or methods to deliver individual 
by-products of heme degradation by HO (e.g., CO and bili-
rubin), would be warranted. From this study, we con-
clude that HO-1 mRNA expression is significantly in-
creased in CLD patients, and the increase reflects the 
severity of the disease. The significant relationship be-
tween the increased HO-1 expression and oxidative stress 
biomarkers in patients with CLD suggest that HO-1 may 
play an important role in protecting the liver from oxida-
tive stress-induced damage. Therefore, the induction of 
HO-1 might be a novel therapeutic option for CLD. How-
ever, large-scale clinical studies are needed to better clar-
ify the exact role of the heme-HO system in CLD and the 
potential clinical applications of inducing the HO-1 sys-
tem.284 Hepat Mon. 2012;12(4)
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